Nephros, Inc. Logo

Nephros, Inc.

NEPH

(1.0)
Stock Price

1,81 USD

-19.71% ROA

-18.26% ROE

-19.68x PER

Market Cap.

36.801.999,00 USD

9.05% DER

0% Yield

-11.07% NPM

Nephros, Inc. Stock Analysis

Nephros, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nephros, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (10%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.44x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROE

Negative ROE (-66.35%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-54.94%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-5), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Nephros, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nephros, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Nephros, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nephros, Inc. Revenue
Year Revenue Growth
2001 300.000
2002 0 0%
2003 0 0%
2004 138.406 100%
2005 2.424.483 94.29%
2006 793.489 -205.55%
2007 1.196.000 33.65%
2008 1.473.000 18.81%
2009 2.661.000 44.64%
2010 2.938.000 9.43%
2011 2.214.000 -32.7%
2012 1.807.000 -22.52%
2013 1.740.000 -3.85%
2014 1.748.000 0.46%
2015 1.944.000 10.08%
2016 2.320.000 16.21%
2017 3.809.000 39.09%
2018 5.687.000 33.02%
2019 10.334.000 44.97%
2020 8.561.000 -20.71%
2021 10.404.000 17.71%
2022 9.975.000 -4.3%
2023 14.968.000 33.36%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nephros, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2001 737.858
2002 957.616 22.95%
2003 1.320.556 27.48%
2004 2.352.604 43.87%
2005 1.756.493 -33.94%
2006 1.844.220 4.76%
2007 1.935.000 4.69%
2008 1.977.000 2.12%
2009 280.000 -606.07%
2010 362.000 22.65%
2011 451.000 19.73%
2012 632.000 28.64%
2013 826.000 23.49%
2014 781.000 -5.76%
2015 826.000 5.45%
2016 1.079.000 23.45%
2017 1.002.000 -7.68%
2018 1.539.000 34.89%
2019 3.090.000 50.19%
2020 2.759.000 -12%
2021 2.166.000 -27.38%
2022 1.255.000 -72.59%
2023 820.000 -53.05%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nephros, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 5.220.250 100%
2005 6.612.999 21.06%
2006 5.718.037 -15.65%
2007 5.527.000 -3.46%
2008 4.702.000 -17.55%
2009 2.812.000 -67.21%
2010 2.520.000 -11.59%
2011 2.636.000 4.4%
2012 3.620.000 27.18%
2013 3.110.000 -16.4%
2014 2.870.000 -8.36%
2015 3.443.000 16.64%
2016 2.854.000 -20.64%
2017 3.298.000 13.46%
2018 4.517.000 26.99%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nephros, Inc. EBITDA
Year EBITDA Growth
2001 -437.858
2002 -1.636.024 73.24%
2003 -4.349.927 62.39%
2004 -7.445.149 41.57%
2005 -6.641.957 -12.09%
2006 -7.679.193 13.51%
2007 11.338.000 167.73%
2008 -6.451.000 275.76%
2009 -2.548.000 -153.18%
2010 -1.730.000 -47.28%
2011 -2.177.000 20.53%
2012 -3.180.000 31.54%
2013 -3.351.000 5.1%
2014 -2.452.000 -36.66%
2015 -3.209.000 23.59%
2016 -2.634.000 -21.83%
2017 -2.004.000 -31.44%
2018 -2.884.000 30.51%
2019 -3.165.000 8.88%
2020 -4.437.000 28.67%
2021 -4.106.000 -8.06%
2022 -4.039.000 -1.66%
2023 -504.000 -701.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nephros, Inc. Gross Profit
Year Gross Profit Growth
2001 300.000
2002 0 0%
2003 0 0%
2004 -73.536 100%
2005 2.045.021 103.6%
2006 -150.237 1461.2%
2007 320.000 146.95%
2008 409.000 21.76%
2009 917.000 55.4%
2010 1.122.000 18.27%
2011 868.000 -29.26%
2012 1.070.000 18.88%
2013 842.000 -27.08%
2014 1.199.000 29.77%
2015 1.060.000 -13.11%
2016 1.294.000 18.08%
2017 2.292.000 43.54%
2018 3.203.000 28.44%
2019 6.084.000 47.35%
2020 4.913.000 -23.83%
2021 5.743.000 14.45%
2022 4.731.000 -21.39%
2023 8.776.000 46.09%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nephros, Inc. Net Profit
Year Net Profit Growth
2001 -1.085.189
2002 -2.417.042 55.1%
2003 -5.636.000 57.11%
2004 -7.596.480 25.81%
2005 -5.468.177 -38.92%
2006 -8.012.911 31.76%
2007 -26.356.000 69.6%
2008 -6.337.000 -315.91%
2009 -2.026.000 -212.78%
2010 -1.933.000 -4.81%
2011 -2.360.000 18.09%
2012 -3.262.000 27.65%
2013 -3.698.000 11.79%
2014 -7.371.000 49.83%
2015 -3.088.000 -138.7%
2016 -3.032.000 -1.85%
2017 -809.000 -274.78%
2018 -3.402.000 76.22%
2019 -3.179.000 -7.01%
2020 -4.724.000 32.71%
2021 -4.165.000 -13.42%
2022 -7.324.000 43.13%
2023 -728.000 -906.04%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nephros, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -123
2002 -273 55.31%
2003 -637 57.08%
2004 -310 -105.83%
2005 -80 -286.25%
2006 -117 31.62%
2007 -303 61.39%
2008 -30 -944.83%
2009 -10 -222.22%
2010 -8 -12.5%
2011 -2 -300%
2012 -3 0%
2013 -2 0%
2014 -3 0%
2015 -1 0%
2016 -1 0%
2017 0 0%
2018 -1 0%
2019 0 0%
2020 -1 0%
2021 0 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nephros, Inc. Free Cashflow
Year Free Cashflow Growth
2001 0
2002 -1.837.114 100%
2003 -3.865.936 52.48%
2004 -8.741.853 55.78%
2005 -5.449.484 -60.42%
2006 -7.409.760 26.46%
2007 -7.579.000 2.23%
2008 -5.822.000 -30.18%
2009 -2.640.000 -120.53%
2010 -1.322.000 -99.7%
2011 -1.296.000 -2.01%
2012 -2.206.000 41.25%
2013 -3.583.000 38.43%
2014 -2.495.000 -43.61%
2015 -3.828.000 34.82%
2016 -2.157.000 -77.47%
2017 -77.000 -2701.3%
2018 -3.662.000 97.9%
2019 -2.290.000 -59.91%
2020 -7.142.000 67.94%
2021 -1.453.000 -391.53%
2022 -3.371.000 56.9%
2023 562.000 699.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nephros, Inc. Operating Cashflow
Year Operating Cashflow Growth
2001 0
2002 -1.806.335 100%
2003 -3.411.956 47.06%
2004 -7.838.981 56.47%
2005 -5.052.194 -55.16%
2006 -7.299.597 30.79%
2007 -7.434.000 1.81%
2008 -5.725.000 -29.85%
2009 -2.612.000 -119.18%
2010 -1.292.000 -102.17%
2011 -1.296.000 0.31%
2012 -1.547.000 16.22%
2013 -3.583.000 56.82%
2014 -2.495.000 -43.61%
2015 -3.815.000 34.6%
2016 -2.112.000 -80.63%
2017 -77.000 -2642.86%
2018 -3.662.000 97.9%
2019 -2.276.000 -60.9%
2020 -6.903.000 67.03%
2021 -1.417.000 -387.16%
2022 -3.234.000 56.18%
2023 562.000 675.44%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nephros, Inc. Capital Expenditure
Year Capital Expenditure Growth
2001 0
2002 30.779 100%
2003 453.980 93.22%
2004 902.872 49.72%
2005 397.290 -127.26%
2006 110.163 -260.64%
2007 145.000 24.03%
2008 97.000 -49.48%
2009 28.000 -246.43%
2010 30.000 6.67%
2011 0 0%
2012 659.000 100%
2013 0 0%
2014 0 0%
2015 13.000 100%
2016 45.000 71.11%
2017 0 0%
2018 0 0%
2019 14.000 100%
2020 239.000 94.14%
2021 36.000 -563.89%
2022 137.000 73.72%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nephros, Inc. Equity
Year Equity Growth
2002 -7.995.193
2003 -5.382.346 -48.54%
2004 9.650.641 155.77%
2005 5.379.493 -79.4%
2006 -2.096.197 356.63%
2007 8.756.000 123.94%
2008 2.534.000 -245.54%
2009 1.958.000 -29.42%
2010 135.000 -1350.37%
2011 1.421.000 90.5%
2012 -595.000 338.82%
2013 -610.000 2.46%
2014 -5.681.000 89.26%
2015 2.664.000 313.25%
2016 667.000 -299.4%
2017 1.950.000 65.79%
2018 6.798.000 71.32%
2019 7.689.000 11.59%
2020 15.573.000 50.63%
2021 14.749.000 -5.59%
2022 8.881.000 -66.07%
2023 8.622.000 -3%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nephros, Inc. Assets
Year Assets Growth
2002 1.279.583
2003 5.033.888 74.58%
2004 12.207.302 58.76%
2005 7.824.575 -56.01%
2006 5.166.698 -51.44%
2007 10.085.000 48.77%
2008 4.036.000 -149.88%
2009 2.652.000 -52.19%
2010 1.590.000 -66.79%
2011 3.994.000 60.19%
2012 3.528.000 -13.21%
2013 2.889.000 -22.12%
2014 3.369.000 14.25%
2015 3.970.000 15.14%
2016 2.678.000 -48.24%
2017 4.983.000 46.26%
2018 10.558.000 52.8%
2019 11.629.000 9.21%
2020 18.510.000 37.17%
2021 17.650.000 -4.87%
2022 10.999.000 -60.47%
2023 10.919.000 -0.73%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nephros, Inc. Liabilities
Year Liabilities Growth
2002 9.274.776
2003 10.416.234 10.96%
2004 2.556.661 -307.42%
2005 2.445.082 -4.56%
2006 7.262.895 66.33%
2007 1.329.000 -446.49%
2008 1.502.000 11.52%
2009 694.000 -116.43%
2010 1.455.000 52.3%
2011 2.573.000 43.45%
2012 4.123.000 37.59%
2013 3.499.000 -17.83%
2014 9.050.000 61.34%
2015 1.306.000 -592.96%
2016 2.011.000 35.06%
2017 3.033.000 33.7%
2018 3.760.000 19.34%
2019 3.940.000 4.57%
2020 2.937.000 -34.15%
2021 2.901.000 -1.24%
2022 2.118.000 -36.97%
2023 2.297.000 7.79%

Nephros, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.29
Net Income per Share
-0.18
Price to Earning Ratio
-19.68x
Price To Sales Ratio
2.72x
POCF Ratio
42.25
PFCF Ratio
36.58
Price to Book Ratio
4.26
EV to Sales
2.43
EV Over EBITDA
-23.28
EV to Operating CashFlow
37.93
EV to FreeCashFlow
32.76
Earnings Yield
-0.05
FreeCashFlow Yield
0.03
Market Cap
0,04 Bil.
Enterprise Value
0,03 Bil.
Graham Number
1.82
Graham NetNet
0.43

Income Statement Metrics

Net Income per Share
-0.18
Income Quality
-0.49
ROE
-0.23
Return On Assets
-0.13
Return On Capital Employed
-0.16
Net Income per EBT
1
EBT Per Ebit
0.99
Ebit per Revenue
-0.11
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.59
Operating Profit Margin
-0.11
Pretax Profit Margin
-0.11
Net Profit Margin
-0.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.08
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.08
Free CashFlow per Share
0.1
Capex to Operating CashFlow
0.16
Capex to Revenue
0.01
Capex to Depreciation
0.63
Return on Invested Capital
-0.18
Return on Tangible Assets
-0.2
Days Sales Outstanding
38.89
Days Payables Outstanding
52.01
Days of Inventory on Hand
146.54
Receivables Turnover
9.38
Payables Turnover
7.02
Inventory Turnover
2.49
Capex per Share
0.01

Balance Sheet

Cash per Share
0,44
Book Value per Share
0,82
Tangible Book Value per Share
0.69
Shareholders Equity per Share
0.82
Interest Debt per Share
0.07
Debt to Equity
0.09
Debt to Assets
0.07
Net Debt to EBITDA
2.71
Current Ratio
4.65
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0.09
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.13
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2197000
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nephros, Inc. Dividends
Year Dividends Growth

Nephros, Inc. Profile

About Nephros, Inc.

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

CEO
Mr. Robert Banks
Employee
27
Address
380 Lackawanna Place
South Orange, 07079

Nephros, Inc. Executives & BODs

Nephros, Inc. Executives & BODs
# Name Age
1 Mr. Alfred Vargas
Director of Operations
70
2 Brianne McGuire
Director of Brand, Marketing & Business Development
70
3 Mr. Daron G. Evans M.B.A., M.S.
Chief Executive Officer of Specialty Renal Products, Inc
70
4 Ms. Judy F. Krandel C.F.A.
Chief Financial Officer
70
5 Mr. Greg Lucas
President of Aether Water Systems
70
6 Mr. Robert Banks
President, Chief Executive Officer & Director
70
7 Vashone R. Thomas
Vice President of Quality, Regulatory, & Human Resources
70
8 Ms. Judy Mazzini
Controller
70

Nephros, Inc. Competitors